FR | EN CONTACT NEWS & EVENTS INVESTORS OUR SCIENCE ABOUT US HOME Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has completed patient enrollment of the Phase 2b study in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. Recent News September 15, 2016 - Poxel Presents New Data on Imeglimin and PXL770 at the European Association for the Study of Diabetes Annual Meeting September 12, 2016 - Poxel Reports Results for First Half 2016 and Provides Corporate Update September 6, 2016 - Poxel to Present at the 18th Annual Rodman & Renshaw Global Investment Conference September 11-13th, 2016 Meet Us At European Large & Mid-Cap Event October 5-6, 2016, Paris, France BIO-Europe November 7-9, 2016, Cologne, Germany Jefferies London Healthcare Conference November 16-17, 2016, London, UK © Poxel SA 2016 Legal Disclaimer | Site Map Home About Us Our Science Investors News & Events Contact

FR | EN CONTACT NEWS & EVENTS INVESTORS OUR SCIENCE ABOUT US HOME Partners Poxel will develop its pipeline programs until clinical proof-of-concept, after which we will seek pharmaceutical industry partners to carry out late-stage clinical development and commercialization. We also collaborate on an ongoing basis with academic leaders in metabolic disease and mitochondrial dysfunction. Poxel has an ongoing fruitful collaboration with Merck Serono, Lyon, France, from which the company was spun out in 2009. In addition, following a longstanding academic collaboration, Poxel as entered into a licensing agreement with newly founded Enyo Pharma, Lyon, France, granting Enyo access to Poxel’s FXR (farnesoid X receptor) agonist compounds for indications outside of Poxel's focus areas. Poxel's academic partners: INSERM U1055, Grenoble, France Hospices Civils de Lyon, Lyon, France Université de Genève, Geneva, Switzerland University Hospital of Ulm, Faculty of Medicine, Ulm, Germany Faculté de Médecine Pierre et Marie Curie, Paris, France Pauls Stradins Clinical University Hospital, Riga, Latvia Yale University, New Haven, CT, USA Karolinska Institutet, Stockholm, Sweden Poxel's industry partners: Merck Serono Enyo Pharma © Poxel SA 2016 Legal Disclaimer | Site Map Home About Us Our Science Investors News & Events Contact